JP2022509448A5 - - Google Patents
Info
- Publication number
- JP2022509448A5 JP2022509448A5 JP2021547964A JP2021547964A JP2022509448A5 JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5 JP 2021547964 A JP2021547964 A JP 2021547964A JP 2021547964 A JP2021547964 A JP 2021547964A JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- atezolizumab
- bevacizumab
- resistant
- signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213116A JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018206076 | 2018-10-31 | ||
| JP2018206076 | 2018-10-31 | ||
| PCT/IB2019/058848 WO2020089722A1 (en) | 2018-10-31 | 2019-10-17 | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213116A Division JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509448A JP2022509448A (ja) | 2022-01-20 |
| JP2022509448A5 true JP2022509448A5 (cg-RX-API-DMAC7.html) | 2024-04-22 |
Family
ID=70463563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547964A Pending JP2022509448A (ja) | 2018-10-31 | 2019-10-17 | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
| JP2024213116A Pending JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213116A Pending JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12577307B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873527A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022509448A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210084560A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114340679A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019372239A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008117A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3115798A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282654A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004709A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202031291A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020089722A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| JP7148037B2 (ja) | 2018-12-03 | 2022-10-05 | イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド | Pd-l1とvegfを標的化する組換えタンパク質 |
| WO2022089377A1 (en) * | 2020-10-26 | 2022-05-05 | Taizhou Eoc Pharma Co., Ltd. | Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer |
| WO2023088436A1 (zh) * | 2021-11-18 | 2023-05-25 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法 |
| TW202444368A (zh) * | 2023-03-30 | 2024-11-16 | 瑞典商米迪維艾克提伯拉公司 | 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法 |
| KR20260116273A (ko) | 2024-09-20 | 2026-07-28 | 파라곤 테라퓨틱스, 인크. | Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| ES2763429T5 (es) | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| DK3858859T3 (da) | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| MX2019010295A (es) | 2017-03-01 | 2019-11-21 | Genentech Inc | Métodos de diagnóstico y terapéuticos para el cáncer. |
-
2019
- 2019-10-17 BR BR112021008117-8A patent/BR112021008117A2/pt not_active Application Discontinuation
- 2019-10-17 MX MX2021004709A patent/MX2021004709A/es unknown
- 2019-10-17 WO PCT/IB2019/058848 patent/WO2020089722A1/en not_active Ceased
- 2019-10-17 KR KR1020217015951A patent/KR20210084560A/ko not_active Withdrawn
- 2019-10-17 CA CA3115798A patent/CA3115798A1/en active Pending
- 2019-10-17 CN CN201980085794.7A patent/CN114340679A/zh active Pending
- 2019-10-17 AU AU2019372239A patent/AU2019372239A1/en not_active Abandoned
- 2019-10-17 JP JP2021547964A patent/JP2022509448A/ja active Pending
- 2019-10-17 US US17/290,197 patent/US12577307B2/en active Active
- 2019-10-17 EP EP19880708.3A patent/EP3873527A4/en active Pending
- 2019-10-18 TW TW108137749A patent/TW202031291A/zh unknown
-
2021
- 2021-04-26 IL IL282654A patent/IL282654A/en unknown
-
2024
- 2024-12-06 JP JP2024213116A patent/JP2025060639A/ja active Pending
-
2026
- 2026-02-17 US US19/542,526 patent/US20260176363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Doebele et al. | Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer | |
| Choi et al. | Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma | |
| Bose et al. | Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care | |
| Dorta-Estremera et al. | Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer | |
| Fan et al. | Systemic therapy for hepatocellular carcinoma: current updates and outlook | |
| Aghajanian et al. | Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer | |
| Kim et al. | A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer | |
| Rougier et al. | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer | |
| Crombet Ramos et al. | Nimotuzumab for patients with inoperable cancer of the head and neck | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| Zhou et al. | Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis | |
| Ruzsa et al. | Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) | |
| Petrelli et al. | Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer | |
| JP2016540042A5 (cg-RX-API-DMAC7.html) | ||
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| JP2016520528A5 (cg-RX-API-DMAC7.html) | ||
| Kerbel | Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer | |
| JP2019532047A5 (cg-RX-API-DMAC7.html) | ||
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Lee et al. | Clinical and cost effectiveness of bevacizumab+ FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea | |
| Xu et al. | Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers | |
| Kirstein et al. | Sequential systemic treatment in patients with hepatocellular carcinoma | |
| Khadela et al. | A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer | |
| Taketomi | Clinical trials of antiangiogenic therapy for hepatocellular carcinoma | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances |